Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Docetaxel 77Radiotherapy 73Prednisone 66Leuprolide 51Goserelin 49Gemcitabine 49Cisplatin 48bicalutamide 46enzalutamide 43Androgen Antagonists 36pembrolizumab 32Abiraterone Acetate 31Mitomycin 29acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 28Magnetic Resonance Spectroscopy 28Carboplatin 27Flutamide 25Nivolumab 24Triptorelin Pamoate 23Sunitinib 23apalutamide 22Radiation 22Doxorubicin 20darolutamide 19abiraterone 18Gonadotropin-Releasing Hormone 18cabozantinib 17atezolizumab 16Specimen Handling 16Radiosurgery 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Technetium Tc 99m Medronate × Genitourinary × Clear all
NCT05614518 2022-11-14

Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECT

HTA Co., Ltd.

Phase 3 Completed
280 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡